Finnegan client BioDelivery Sciences International (BDSI) prevailed over Alvogen PB Research and Development in the District of Delaware after the judge upheld claims in two patents (U.S. Patent No. 8,147,866 and U.S. Patent No. 9,901,539) related to BDSI's opioid pain medication Belbuca, which BDSI accused Alvogen of infringing. Belbuca is a chronic pain treatment that uses buccal film technology to deliver buprenorphine and is BDSI’s core product, with sales over $100 million per year.
Finnegan partner Justin Hasford said, “We are very pleased that Chief Judge Connolly found that Alvogen failed to prove its invalidity case with respect to claims 4 and 5 of the '866 patent and claims 9 and 20 of the '539 patent."
Read “Del. Judge Upholds Claims in Opioid Drug IP But Axes Others”
Award/Ranking
Finnegan Named Firm of the Year at the 2024 Managing Intellectual Property Americas Awards
April 26, 2024
Commentary
April 11, 2024
Media Mention
Women in Business Law Americas Awards 2024: Three Finnegan Attorneys Shortlisted
April 7, 2024
Press Release
Finnegan and BMW Group Successfully Demolish Non-Practicing Entity NorthStar’s Efforts
April 3, 2024
Due to international data regulations, we’ve updated our privacy policy. Click here to read our privacy policy in full.
We use cookies on this website to provide you with the best user experience. By accepting cookies, you agree to our use of cookies. Please note that if you opt not to accept or if you disable cookies, the “Your Finnegan” feature on this website will be disabled as well. For more information on how we use cookies, please see our Privacy Policy.
Finnegan is thrilled to announce the launch of our new blog, Ad Law Buzz, devoted solely to breaking news, developments, trends, and analysis in advertising law.